Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Humacyte (HUMA – Research Report). The associated price target remains the same with $15.00.
Vernon Bernardino has given his Buy rating due to a combination of factors including the recent commercial launch of Symvess, which marks a significant growth phase for Humacyte. The FDA’s full approval of Symvess for use in adults as a vascular conduit in critical situations underscores its potential impact in the medical field. The pricing strategy for Symvess, set at $29,500 per unit, aligns closely with market expectations and is considered reasonable given the potential cost savings in treating severe vascular injuries.
Furthermore, Humacyte’s development of a Budget Impact Model (BIM) highlights the economic advantages of Symvess, projecting lower treatment costs compared to current standard-of-care options. Clinical studies have shown significant reductions in amputation and infection rates, which are major cost drivers, thereby enhancing the product’s appeal to healthcare providers. As hospitals continue their review process and gain experience with Symvess, its adoption is expected to accelerate, supporting the Buy rating and the $15 price target.
Bernardino covers the Healthcare sector, focusing on stocks such as Novavax, Aethlon Medical, and Cardiol Therapeutics. According to TipRanks, Bernardino has an average return of 5.1% and a 24.80% success rate on recommended stocks.
In another report released on February 26, TD Cowen also maintained a Buy rating on the stock with a $10.00 price target.